Abstract
The clinical observation of the multidrug resistance (MDR) phenotype is often associated with overexpression of the mdr1 gene, in particular with respect to ovarian cancer. However, until now the mdr1-inducing potential of commonly used antineoplastics has been only incompletely explored. We performed short-term cultures of six ovarian cancer cell lines (MZOV4, EFO27, SKOV3, OAW42, OTN14, MZOV20) exposed to either blank medium or cisplatin, doxorubicin or paclitaxel at concentrations related to the clinically achievable plasma peak concentration. A highly specific quantitative real-time RT-PCR was used to detect the Mdr1 transcripts. Mdr1 mRNA contents were calibrated in relation to coamplified GAPDH mRNA. Mdr1 mRNA was detectable in each cell line. In 13 out of 18 assays (72%) the specific anticancer drug being tested induced mdr1 transcription. No decrease in mdr1 mRNA concentration was observed. Our data suggest that mdr1 induction by antineoplastics is one of the reasons for failure of ovarian cancer therapy but may vary individually.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5:3352–3356
Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB (2000) P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 20:1061–1067
Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavsson B, Kristensen GB (2001) Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 19:2983–2993
Beck JF, Bohnet B, Brugger D, Dietl J, Scheper RJ, Bader P, Niethammer D, Gekeler V (1998) Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res 18:701–705
Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, DIncalci M (1997) Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65:130–137
Fracasso PM (2001) Overcoming drug resistance in ovarian carcinoma. Curr Oncol Rep 3:19–26
Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP (2001) Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 19:2975–2982
Friedlander ML (1998) Prognostic factors in ovarian cancer. Sem Oncol 25:305–314
Goff BA, Ries JA, Els LP, Coltrera MD, Grown AM (1998) Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 70:378–385
Joncourt F, Buser K, Altermatt H, Bacchi M, Oberli A, Cerny T (1998) Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol 70:176–182
Kavallaris M, Leary JA, Barrett JA, Friedlander ML (1996) MDR1 and multidrug resistance associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 102:7–16
Lehne G (2000) P-glycoprotein as a drug target in the treatment of multidrug resistance cancer. Curr Drug Targets 1:85–99
Masanek U, Stammler G, Volm M (1997) Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anticancer Drugs 8:189–198
Moran E, Cleary I, Larkin AM, Nic Amhlaoibh R, Masterson A, Scheper RJ, Izquierdo MA, Center M, ÓSullivan F, Clynes M (1997) Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur J Cancer 33:652–660
Peck RA, Hewett J, Harding MW, Wang YM, Chauturvedi PR, Bhatnagar A, Ziessmann H, Atkins F, Hawkins MJ (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19:3130–3141
Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller Jr, AF, Goodmann A, Nikrui N, Seiden MV (2000) Expression of multidrug resistance-1 (MDR-1) correlates with paclitaxel response in ovarian cancer (OVCA) patients. Proc ASCO 19:399a.
Robert J (1999) Multidrug resistance in oncology: Diagnostic and therapeutic approaches. Eur J Clin Invest 129:536–545
Schneider J, Jimenez E, Marenbach K, Marx D, Meden H (1998) Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 18:2967–2971
Schöndorf T, Scharl A, Kurbacher CM, Bien O, Becker M, Neumann R, Kolhagen H, Rustemeyer J, Mallmann P, Göhring U-J (1999) Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett 146:195–199
Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP (2000) Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 78:130–136
Yang X, Page M (1995) P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res 7:619–624
Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25:387–394
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schöndorf, T. et al. (2003). Cisplatin, Doxorubicin and Paclitaxel Induce mdr1 Gene Transcription in Ovarian Cancer Cell Lines. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive